2024-10-26 - Analysis Report
## Danaher Corp (DHR) Stock Analysis Report

**Company Overview:** Danaher Corp is a global science and technology innovator, developing and manufacturing a wide range of products and services across various industries.

**Performance Analysis:**

**1. Outperformance vs. S&P 500:**
* **Cumulative Return:** DHR (218.33) significantly outperformed the S&P 500 (VOO) (135.48).
* **Relative Outperformance:** DHR's relative outperformance is currently at 82.85, which is in the top 37.99% percentile compared to its historical performance against the S&P 500.

**2. Recent Price Movements:**
* **Closing Price:** $248.0 (Last Market: $245.16)
* **Moving Averages:**
    * 5-Day: $263.55
    * 20-Day: $269.48
    * 60-Day: $270.14
* **Observation:**  DHR is currently trading below its 5, 20, and 60-day moving averages, suggesting a short-term downtrend.

**3. Technical Indicators:**
* **RSI:** 27.31 –  Suggests oversold conditions, potentially indicating a rebound.
* **PPO:** -0.79 – Indicates a bearish momentum.
* **Delta_Previous_Relative_Divergence:** -16.74 – Indicates a recent decrease in relative outperformance.
* **Expected Return:** 63.09% –  Implies a strong potential for long-term outperformance compared to the S&P 500.
* **Observation:** Technical indicators suggest a short-term downtrend, but long-term prospects remain positive.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-22 | 1.13 | 5.80 B$ |
| 2024-07-23 | 1.23 | 5.74 B$ |
| 2024-04-23 | 1.47 | 5.80 B$ |
| 2024-02-21 | 1.46 | 6.41 B$ |
| 2023-10-24 | 1.53 | 5.62 B$ |

* **Analysis:**  The most recent earnings for Q3 2024 (Oct 22, 2024) showed a slight dip in both EPS and Revenue compared to the previous quarter. However, analysts are optimistic about DHR's future prospects.  
* **Expected Earnings:**  The expected earnings for Q3 2024 were not provided in the provided data.

**5. News & Recent Issues:**

* **Recent Earnings News:**  No recent earnings news was found in the provided data.
* **Market Outlook:**  Analyst opinions on DHR are generally positive, with many highlighting its strong growth prospects in key industries such as healthcare and life sciences. 
* **Analyst Opinions:**  According to FINBOLD, DHR has a "Strong Buy" rating from analysts with a consensus price target of $280.07.

**6. Summary:**

* DHR has demonstrated strong historical outperformance against the S&P 500 and holds promising long-term prospects. 
* Recent price movements indicate a short-term downtrend, but technical indicators suggest a potential rebound.
* Earnings for the latest quarter show a slight dip, but analysts are optimistic about DHR's future performance.

**7. Overall:**

DHR remains a solid investment opportunity, with a strong track record and positive future prospects. While recent price movements indicate a short-term downtrend, the long-term outlook remains positive. Investors seeking long-term growth potential may consider DHR as a potential addition to their portfolios.

**Disclaimer:** This report is for informational purposes only and should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions.